Früher|Nächster

Verbesserung der Platinresistenz des nicht-kleinzelligen Lungenkrebses durch die Regulation von PCBP1 und die Induktion des Eisentodes

  • role： First author第一作者
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

  • Email：1047928253@qq.com
  • Introduction：刘玥彤，硕士，从事中医药抗肿瘤基础研究，E-mail：1047928253@qq.com
LIU Yuetong,  
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

LI He,  
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

MU Qirui,  
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

HUANG Jingyi,  
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

CAI Haoran,  
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

LIU Chunying,  
  • role： Corresponding author通信作者
  • Affiliation：

    College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

  • Email：gaoyuan.laury@163.com
  • Introduction：高原，博士，教授，从事中医药抗肿瘤基础研究，E-mail：gaoyuan.laury@163.com
GAO Yuan*

Resümee

Das Ziel dieser Studie ist es, den molekularen Mechanismus zur Verbesserung der Platinresistenz des nicht-kleinzelligen Lungenkrebses (NSCLC) durch Regulation des Polyparaden 1 (PCBP1) und Induktion des Eisentodes zur Verbesserung von Shunplatinum zu erkunden.

Schlüsselwort

Bu Zhong Yi Qi Tang؛ Nicht-kleinzelliger Lungenkrebs (NSCLC)؛ Polymerasekettenreaktion 1 (PCBP1)؛ Eisentod; Platinresistenz

References

  1. 1.
    SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71（3）：209-249.
  2. 2.
    WATHONI N，PULUHULAWA L E，JONI I M，et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer［J］. Drug Deliv，2022，29（1）：2959-2970.
  3. 3.
    MATHIEU L N，LARKINS E，SINHA A K，et al. FDA approval summary：Atezolizumab as adjuvant treatment following surgical resection and platinum-based chemotherapy for stage Ⅱ to ⅢA NSCLC［J］. Clin Cancer Res，2023，29（16）：2973-2978.
  4. 4.
    KRYCZKA J，BONCELA J. Cell migration related to MDR-another impediment to effective chemotherapy？［J］. Molecules，2018，23（2）：331.
  5. 5.
    MU Q R，LI H，LIU Y T， et al. Buzhong Yiqitang regulates apoptosis via Nrf2/ROS pathway to alleviate cisplatin resistance in A549/DDP cells［J］.Chin J Exper Tradit Med Form，2024，30（1）：95-102.
  6. 6.
    WU X Y，LI H G.Research progress on immunomodulatory effects of Fuzheng therapy in TCM for lung cancer［J］.World J Integr Tradit West Med，2022，17（8）：1691-1696．
  7. 7.
    WANG Y C，JIAO L J，ZHANG B Y，et al.Analysis of clinical efficacy and related factors of "treating Qi first" rehabilitation therapy for postoperative symptoms of lung cancer［J］.China J Tradit Chin Med Pharm，2021，36（5）：2694-2698.
  8. 8.
    WANG C H.Meta-analysis and trial sequential analysis of the efficacy and safety of traditional Chinese medicine combined with gefitinib in the treatment of advanced non-small cell lung cancer［J］.J Chin Med Mater，2019，42（8）：1938-1946.
  9. 9.
    YIN Y H，JIA X H.The application of the method of banking up earth for generating metal in the treatment of bronchial asthma in remission［J］.World Lat Med Inf，2018，18（28）：178-180.
  10. 10.
    JIANG X，STOCKWELL BR，CONRAD M. Ferroptosis：Mechanisms，biology and role in disease［J］. Nat Rev Mol Cell Biol， 2021，22（4）：266-282.
  11. 11.
    WU Q B，SHENG X，ZHANG N，et al. Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy［J］. Mol Clin Oncol，2018：8（4）：523-527.
  12. 12.
    MANZ D H，BLANCHETTE N L，PAUL B T，et al. Iron and cancer：Recent insights［J］. Ann N Y Acad Sci，2016，1368（1）：149-161.
  13. 13.
    OZKAN E，BAKAR-ATES F. Ferroptosis：A trusted ally in combating drug resistance in cancer［J］. Curr Med Chem，2022，29（1）：41-55.
  14. 14.
    TANG R，XU J，ZHANG B，et al. Ferroptosis， necroptosis， and pyroptosis in anticancer immunity［J］. J Hematol Oncol， 2020：13（1）：110.
  15. 15.
    HASSANNIA B，VANDENABEELE P，VANDEN BERGHE T. Targeting ferroptosis to iron out cancer［J］. Cancer Cell， 2019：35（6）：830-849.
  16. 16.
    ROH J L，KIM E H，JANG H J，et al. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer［J］. Cancer Lett，2016，381（1）：96-103.
  17. 17.
    LEE J，YOU J H，ROH J L. Poly（rC）-binding protein 1 represses ferritinophagy-mediated ferroptosis in head and neck cancer［J］. Redox Biol，2022，51：102276.
  18. 18.
    ZHENG J，CONRAD M. The metabolic underpinnings of ferroptosis［J］. Cell Metab，2020，32（6）：920-937.
  19. 19.
    ZHANG T，HUANG X H，DONG L，et al. PCBP-1 regulates alternative splicing of the CD44 gene and inhibits invasion in human hepatoma cell line HepG2 cells［J］. Mol Cancer，2010，9：72.
  20. 20.
    JADHAV S，PROTCHENKO O，LI F，et al. Mitochondrial dysfunction in mouse livers depleted of iron chaperone PCBP1［J］. Free Radic Biol Med，2021，175：18-27.
  21. 21.
    DOU T，ZHU X G，YANG H.Research progress on ferroptosis in hepatocellular carcinoma［J］.Chin J Liver Dis （Elec Version），2023，15（4）：6-10.

Lesen Sie die ganze Passage

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website